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EBOLA VIRUS VACCINES
Authors’ reply to Kremer and Van de Perre
Nicholas J Beeching senior lecturer (honorary consultant) 1, Manuel Fenech specialist trainee in
infectious diseases 2, Catherine F Houlihan clinical research fellow 3
1Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK; 2Royal Liverpool University Hospital, Liverpool, UK; 3London School of Hygiene and
Tropical Medicine, London, UK
Kremer and Van de Perre highlight important concerns.1 2 HIV
incidence was increased mainly in men in the long term
follow-up (3.5 years after vaccination) of the Phambili HIV
vaccine trial, which used an adenovirus type 5 vectored DNA
vaccine.3 The candidate Ebola adenovirus vectored vaccine is
of a different adenovirus subtype (type 3).4 5 However, the
postulated mechanism of increased HIV risk—an increase in
adenovirus type specific T cells, targets for HIV that could
migrate to the gut and genitalia—may still apply.
HIV-1 prevalence in young adults in the three west African
countries worst affected by Ebola is estimated at 1.1% (Liberia),
1.6% (Sierra Leone), and 1.7% (Guinea), much lower than in
South Africa (19.1%), where the Phambili trial was conducted
(www.unaids.org/en/dataanalysis/datatools/aidsinfo). Ebola
vaccine trials, including those using adenovirus vectors, should
not be delayed. However, long term follow-up of study
participants, including voluntary HIV counselling and testing,
should be planned. Study participants should be made aware of
the potential risk.3
Concern has been expressed about the effect of the Ebola
outbreak on delivery of routine healthcare to people with HIV
in affected countries.6 Parallels have been drawn between the
stigma experienced by people living with HIV, survivors of
Ebola, and healthcare workers looking after people with either
infection.6 Yet there are no current data on the clinical
presentation or prognosis of Ebola in people infected with HIV
, including those taking antiretrovirals. It has been suggested
that protease inhibitors and perhaps lamivudine have a protective
effect.7 8 Survivors infected with HIVmight also maintain Ebola
virus in sanctuary sites, such as semen, for longer than currently
described.9 Information is needed on dual infection with HIV
and Ebola, and interventional studies and reports on outcomes
from Ebola treatment centres in west Africa should consider
this potential confounder.
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